Showing 2441-2450 of 9963 results for "".
Exosomes 101
https://practicaldermatology.com/conferences/scale-2023/exosomes-101/20192/Exosomes are today's hottest skincare ingredient, and Glynis Ablon, MD, gives viewers the scoop on how and when to use them.DermWireTV: Diversity in Dermatology; Inclusive Beauty Initiatives; Eczema Awareness Month
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-diversity-in-dermatology-inclusive-beauty-initiatives-eczema-awareness-month/20152/La Roche-Posay and the Women's Dermatologic Society have partnered to sponsor a Fellowship in the Department of Dermatology at Howard University's College of Medicine for Underrepresented in medicine medical students. WDS President Mona Gohara, MD shares insights about the need to support DEI in derRadiesse Plus Launches, AAD Convenes, NPF Registry Begins
https://practicaldermatology.com/topics/psoriasis/dermwiretv-radiesse-plus-launches-aad-convenes-npf-registry-begins--epesurag/18939/In this edition of DermWireTV: Merz Aesthetics launches Radiesse Plus with lidocaine for the treatment of facial wrinkles and folds and the National Psoriasis Foundation (NPF) launches new patient registry focused on patient safety. Plus, updates from the annual meeting of the American Academy of DeConnective Tissue Disorders Update 2025: Dr. Vleugels
https://practicaldermatology.com/programs/practical-dermatology/connective-tissue-disorders-update-2025-dr-vleugels/32673/Ruth Ann Vleugels, MD, PhD, recaps her presentation, "Connective Tissue Disorders Update 2025" at Maui Derm 2025. Dr. Vleugels discussed a new therapeutic for systemic lupus, a new FDA-approved option for dermatomyositis, JAK inhibitors, and more.The Impact of Clascoterone Topical Cream, 1%
https://practicaldermatology.com/issues/april-2025/the-impact-of-clascoterone-topical-cream-1/35605/Clascoterone topical cream, 1% (Winlevi, Sun Pharmaceuticals, Inc.) approved by the US Food and Drug Administration (FDA) in 2020 as the first novel drug introduced for the treatment of acne vulgaris since 1982, is indicated in the US for patients 12 years of age and older.The View from Under the Hood
https://practicaldermatology.com/issues/january-february-2025/the-view-from-under-the-hood/32967/As 2025 brings new approvals for treatments for hidradenitis suppurativa, chronic spontaneous urticaria, psoriatic arthritis, and several other diseases that need answers, this is a good time for us to remember that the most important approach to treatment starts with the right diagnosis.Dupilumab's Impact on Height, 40-GEP for HNcSCC Lead Posters at Maui Derm
https://practicaldermatology.com/programs/practical-dermatology/dupilumabs-impact-on-height-40-gep-for-hncscc-lead-posters-at-maui-derm/32916/The impact of dupilumab on children’s height and the 40-gene expression profile (40-GEP) test for patients with cutaneous squamous cell carcinoma of the head and neck (HNcSCC) were the topics of the top two posters in the “Late Breakers 2025” session at Maui Derm 2025 in Maui, Hawaii.Acne and Rosacea: Dr. Baldwin
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/acne-and-rosacea-dr-baldwin/32693/Hilary Baldwin, MD, talks about a topic that she did not have time to cover during "Update 2025: Acne and Rosacea" at Maui Derm 2025—emergency contraception in patients on isotretinoin.Psoriasis Update 2025: Dr. Gelfand
https://practicaldermatology.com/conferences/maui-derm-hawaii-2025/psoriasis-update-2025-dr-gelfand/32672/Joel Gelfand, MD, MSCE, discusses highlights from the "Psoriasis Update 2025" panel at Maui Derm 2025, including the potential for combining TNF inhibitors with IL-23 inhibitors; home phototherapy; and the possibility of GLP-1 agonists lowering the severity of psoriatic disease.American Academy of Dermatology 2024
Meeting Wrap-Uphttps://practicaldermatology.com/cme/dermatology/meeting-coverage-aad-2024/24461/Practical Dermatology® was at the American Academy of Dermatology 2024 Annual Meeting in San Diego (AAD 2024) reporting on the latest research findings on innovative therapies and insights into managing complex dermatological disorders. From pioneering trials showcasing the efficacy of novel topical